New mRNA shingles shot shows promise in early trial
NCT ID NCT06375512
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new mRNA vaccine called IN001 for preventing shingles in 150 healthy adults aged 50 to 69. The main goals were to check the vaccine's safety, side effects, and how well it triggers the immune system. Researchers gave different doses to find the best balance of protection and tolerability.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HERPES ZOSTER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CenExel
Hollywood, Florida, 33024, United States
-
Emeritus Research Pty Ltd
Sydney, New South Wales, 2019, Australia
-
Emeritus Research Pty Ltd
Melbourne, Victoria, 3124, Australia